Fund Holdings — Patient Square Capital LP

Total Portfolio Value:
$467.13M
Total Bought:
$130.23M
Total Sold:
$48.02M
Net Transaction:
+$82.21M
Securities
▲▼
SharesValue
Q3 2025
▲▼
Q4 2025
▲▼
Change
▲▼
Q3 2025
▲▼
Q4 2025
▲▼
Weight (%)
▲▼
Change
▲▼
Roivant Sciences Ltd.SHS(ROIV)12,480,0008,166,047-4,313,953$188.82M$177.20M37.93%-$11.62M
Insmed Incorporated(INSM)326,400267,000-59,400$47.00M$46.47M9.95%-$536.2K
Mirum Pharmaceuticals, Inc.(MIRM)104,262298,682+194,420$7.64M$23.59M5.05%+$15.95M
argenx SEADR(ARGX)15,50026,000+10,500$11.43M$21.86M4.68%+$10.43M
BeOne Medicines AGADS(ONC)069,312+69,312$0$21.06M4.51%+$21.06M
ABIVAX Société AnonymeADS(ABVX)151,833130,000-21,833$12.89M$17.53M3.75%+$4.64M
Pharvaris N V
COM
345,381542,696+197,315$8.62M$15.06M3.22%+$6.44M
EyePoint, Inc.(EYPT)1,011,839780,000-231,839$14.41M$14.25M3.05%-$158.0K
Terns Pharmaceuticals Inc0320,000+320,000$0$12.93M2.77%+$12.93M
Celcuity Inc.(CELC)100,000120,000+20,000$4.94M$11.97M2.56%+$7.03M
Cogent Biosciences, Inc.(COGT)0317,372+317,372$0$11.27M2.41%+$11.27M
Kymera Therapeutics, Inc.(KYMR)92,592139,000+46,408$5.24M$10.82M2.32%+$5.57M
Liquidia Corporation(LQDA)400,000227,000-173,000$9.10M$7.83M1.68%-$1.27M
DBV Technologies S.A.ADS(DBVT)0359,050+359,050$0$6.88M1.47%+$6.88M
Allogene Therapeutics Inc2,981,3964,963,756+1,982,360$3.70M$6.80M1.46%+$3.10M
Dianthus Therapeutics, Inc.(DNTH)125,000150,000+25,000$4.92M$6.18M1.32%+$1.26M
Xenon Pharmaceuticals Inc.(XENE)0136,500+136,500$0$6.12M1.31%+$6.12M
Arcutis Biotherapeutics, Inc.(ARQT)0210,000+210,000$0$6.10M1.31%+$6.10M
Ocular Therapeutix, Inc.(OCUL)715,000490,000-225,000$8.36M$5.95M1.27%-$2.41M
Disc Medicine, Inc.(IRON)74,00074,0000$4.89M$5.88M1.26%+$986.4K
Avalo Therapeutics, Inc.(AVTX)100,000311,966+211,966$1.27M$5.67M1.21%+$4.39M
Spyre Therapeutics, Inc.(SYRE)0150,000+150,000$0$4.91M1.05%+$4.91M
Enliven Therapeutics Inc250,838308,141+57,303$5.13M$4.75M1.02%-$389.3K
Assembly Biosciences Inc135,182127,000-8,182$3.46M$4.32M0.92%+$858.6K
Amylyx Pharmaceuticals, Inc.(AMLX)316,312350,000+33,688$4.30M$4.23M0.91%-$70.7K
Arcus Biosciences, Inc.(RCUS)0170,000+170,000$0$4.05M0.87%+$4.05M
Perspective Therapeutics, Inc.(CATX)349,3231,132,815+783,492$1.20M$3.12M0.67%+$1.92M
Harrow, Inc.(HROW)07,031+7,031$0$344.5K0.07%+$344.5K
Agios Pharmaceuticals, Inc.(AGIO)133,8270-133,827$5.37M$0—-$5.37M
Cidara Therapeutics Inc121,0000-121,000$11.59M$0—-$11.59M
Geron Corporation(GERN)845,0000-845,000$1.16M$0—-$1.16M
Nurix Therapeutics, Inc.(NRIX)437,2370-437,237$4.04M$0—-$4.04M
uniQure N.V.SHS(QURE)75,0000-75,000$4.38M$0—-$4.38M
Page 1 of 1
Patient Square Capital LP — 13F Holdings — Q4 2025 | TickerTrail